1. Search Result
Search Result
Results for "

genotype 4 HCV

" in MedChemExpress (MCE) Product Catalog:

437

Inhibitors & Agonists

3

Screening Libraries

8

Fluorescent Dyes

5

Biochemical Assay Reagents

30

Peptides

7

Inhibitory Antibodies

33

Natural
Products

8

Recombinant Proteins

24

Isotope-Labeled Compounds

12

Click Chemistry

16

Oligonucleotides

1

GMP Molecules

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N6798
    Myriocin
    Maximum Cited Publications
    11 Publications Verification

    Thermozymocidin; ISP-I

    HCV Antibiotic Infection
    Myriocin (Thermozymocidin), a fungal metabolite could be isolated from Myriococcum albomyces, Isaria sinclairi and Mycelia sterilia, is a potent inhibitor of serine-palmitoyl-transferase (SPT) and a key enzyme in de novo synthesis of sphingolipids. Myriocin suppresses replication of both the subgenomic HCV-1b replicon and the JFH-1 strain of genotype 2a infectious HCV, with an IC50 of 3.5 μg/mL for inhibiting HCV infection .
    Myriocin
  • HY-10466
    Daclatasvir
    45+ Cited Publications

    BMS-790052; EBP 883

    HCV Infection
    Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC50s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC50s of 1.5 µM and 3.27 µM, respectively .
    Daclatasvir
  • HY-19840

    GS-9857

    HCV Protease Infection Cancer
    Voxilaprevir (GS-9857) is a noncovalent, reversible inhibitor of HCV NS3/4A protease inhibitor (PI) with pangenotypic antiviral activity . Voxilaprevir inhibits genotype 1b and 3a wild-type NS3 proteases with Ki values of 0.038 nM and 0.066 nM, respectively . Voxilaprevir is an orally active direct-acting antiviral agent (DAA) and can be used for HCV infection research .
    Voxilaprevir
  • HY-13998
    Dasabuvir
    10+ Cited Publications

    ABT-333

    HCV DNA/RNA Synthesis Infection
    Dasabuvir (ABT-333) is a nonnucleoside hepatitis C virus (HCV) polymerase inhibitor. Dasabuvir inhibits RNA-dependent RNA polymerase encoded by the HCV NS5B gene. Dasabuvir inhibits genotype 1a (strain H77) and 1b (strain Con1) replicons, with EC50 values of 7.7 and 1.8 nM, respectively .
    Dasabuvir
  • HY-10465
    Daclatasvir dihydrochloride
    45+ Cited Publications

    BMS-790052 dihydrochloride; EBP 883 dihydrochloride

    HCV Infection
    Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) is a potent and orally active HCV NS5A protein inhibitor with EC50s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir dihydrochloride is also an organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC50s of 1.5 μM and 3.27 μM, respectively .
    Daclatasvir dihydrochloride
  • HY-109035
    Inarigivir soproxil
    1 Publications Verification

    SB9200; GS-9992

    HCV HBV Infection
    Inarigivir soproxil (SB9200) is an agonist of innate immunity and shows potent antiviral activity against resistant HCV variants, with EC50s of 2.2 and 1.0 μM for HCV 1a/1b in cells of genotype 1 HCV replicon systems. Inarigivir soproxil, an orally bioavailable proagent of SB 9000, has broad-spectrum antiviral activity against RNA viruses including HCV, norovirus, respiratory syncytial virus and influenza and HBV .
    Inarigivir soproxil
  • HY-13997
    Ombitasvir
    5+ Cited Publications

    ABT-267

    HCV Infection
    Ombitasvir is a potent inhibitor of the hepatitis C virus protein NS5A, with EC50s of 0.82 to 19.3 pM against HCV genotypes 1 to 5, and 366 pM against genotype 6a.
    Ombitasvir
  • HY-101662

    ABT-530

    HCV Infection
    Pibrentasvir is a novel and pan-genotypic hepatitis C virus (HCV) NS5A inhibitor with EC50s ranging from 1.4 to 5.0 pM against HCV replicons containing NS5A from genotypes 1 to 6.
    Pibrentasvir
  • HY-10242

    BILN 2061; BILN 2061ZW

    HCV HCV Protease DNA/RNA Synthesis Infection
    Ciluprevir (BILN 2061; BILN 2061ZW) is an orally active macrocyclic peptide inhibitor of hepatitis C virus (HCV)NS3 protease, with an IC50 of 3 nM. Ciluprevir has Kᵢ values of 0.66 nM and 0.30 nM against genotypes 1b and 1a, respectively. Ciluprevir inhibits HCV RNA replication with an EC50 of 1.2 nM, and its EC50 values against genotypes 1b and 1a are 3 nM and 4 nM, respectively. Ciluprevir shows no significant inhibition against human leukocyte elastase and hepatic cathepsin B. Ciluprevir can be used for genotype 1 HCV infection .
    Ciluprevir
  • HY-14775
    Nesbuvir
    5+ Cited Publications

    HCV-796

    HCV Infection
    Nesbuvir is a nonnucleoside inhibitor of the hepatitis C virus (HCV) nonstructural protein 5B (NS5B) polymerase.
    Nesbuvir
  • HY-124191

    PPI-668 hydrochloride

    HCV Infection
    Ravidasvir hydrochloride (PPI-668 hydrochloride) is a pan-genotypic inhibitor for hepatitis C virus (HCV) NS5A protein. Ravidasvir hydrochloride inhibits the replication of HCV, with EC50 of 0.12, 0.01 and 1.14 nM, for HCV gt-1a, gt-1b, and gt-3a replicons, respectively. Ravidasvir hydrochloride exhibits good pharmacokinetic characters in rats .
    Ravidasvir hydrochloride
  • HY-12429
    Beclabuvir
    5 Publications Verification

    BMS-791325

    DNA/RNA Synthesis HCV Infection
    Beclabuvir is an allosteric inhibitor that binds to thumb site 1 of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, and inhibits recombinant NS5B proteins from HCV genotypes 1, 3, 4, and 5 with IC50 of < 28 nM .
    Beclabuvir
  • HY-147358

    Emitasvir diphosphate; DAG-181 diphosphate

    HCV Infection
    Yimitasvir diphosphate (Emitasvir diphosphate; DAG-181 diphosphate) is an orally active inhibitor of hepatitis C virus (HCV) nonstructural protein 5A (NS5A). Yimitasvir diphosphate is applicable to research related to HCV infection .
    Yimitasvir diphosphate
  • HY-13465
    VCH-916
    1 Publications Verification

    HCV Infection
    VCH-916 is a thiophene derivative and non-nucleoside inhibitor of HCV NS5B polymerase with sub-micromolar IC50 values versus genotype 1a and 1b replicons. VCH-916 binds to Thumb Site II. VCH-916 can be used for the research of hepatitis c virus (hcv) infection .
    VCH-916
  • HY-16784
    Samatasvir
    1 Publications Verification

    IDX719; IDX18719

    HCV HCV Protease Infection
    Samatasvir (IDX71) is a potent, orally active NS5A inhibitor of HCV replication. Samatasvir is effective and selective against infectious HCV and replicons, with EC50s falling within a tight range of 2 to 24 pM in genotype 1 through 5 replicons .
    Samatasvir
  • HY-138305

    HCV Infection Inflammation/Immunology
    HCV-IN-31 (compound 4) is a HCV inhibitor, with an EC50/EC95 of 15.7 μM for HCV replicon .
    HCV-IN-31
  • HY-136266

    HCV Cancer
    HCV-IN-29 is a hepatitis C virus (HCV) inhibitor exacted from patent US8329159B2, compound 1e .
    HCV-IN-29
  • HY-10465R

    BMS-790052 dihydrochloride (Standard); EBP 883 dihydrochloride (Standard)

    Reference Standards HCV Infection
    Daclatasvir (dihydrochloride) (Standard) is the analytical standard of Daclatasvir (dihydrochloride). This product is intended for research and analytical applications. Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) is a potent and orally active HCV NS5A protein inhibitor with EC50s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir dihydrochloride is also an organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC50s of 1.5 µM and 3.27 µM, respectively .
    Daclatasvir dihydrochloride (Standard)
  • HY-19558

    HCV HCV Protease Infection
    IDX184 is a potent and orally bioavailable inhibitor of HCV replication. IDX184 potently inhibits HCV polymerase (IC50=0.31 μM, Ki=52.3 nM) .
    IDX184
  • HY-P4035

    HCV Infection
    HCV NS4A Protein (18-40) (JT strain) is an HCV NS4A peptide, which comprised residues 18 to 40 of the NS4A protein and is known to increase the catalytic efficiency of NS3 protease .
    HCV NS4A Protein (18-40) (JT strain)
  • HY-N8188

    HCV HCV Protease Infection
    Dehydrojuncusol, a potent HCV inhibitor, targets HCV NS5A and is able to inhibit RNA replication of replicons harboring resistance mutations to anti-NS5A direct-acting antivirals. Dehydrojuncusol significantly inhibits HCV infection when added after virus inoculation of HCV genotype 2a (EC50=1.35?μM) .
    Dehydrojuncusol
  • HY-147358A

    Emitasvir; DAG-181

    HCV Infection
    Yimitasvir (Emitasvir; DAG-181) is an orally active inhibitor of hepatitis C virus (HCV) nonstructural protein 5A (NS5A). Yimitasvir is applicable to research related to HCV infection .
    Yimitasvir
  • HY-P4036

    HCV Infection
    HCV Core Protein (59-68) is a peptide containing residues 59-68 of the HCV core protein .
    HCV Core Protein (59-68)
  • HY-P4029

    HCV Infection
    HCV-1 e2 Protein (484-499) is a peptide consisting of 16 amino acids. HCV-1 e2 Protein (484-499) is derived from the envelope 2 protein of hepatitis C virus in the sera from individuals with antibodies to HCV .
    HCV-1 e2 Protein (484-499)
  • HY-P0162

    HCV Infection
    HCV-IN-4 is a potent and orally active HCV NS5A inhibitor, shows great potency against GT1a, GT2b, GT3a, GT1a Y93H and GT1a L31V, with EC90s of 3 pM, 0.3 nM, 0.01 nM, 0.5 nM and 0.02 nM, respectively .
    HCV-IN-4
  • HY-N7934

    (-)-Trachelogenin

    HCV Infection Neurological Disease Inflammation/Immunology
    Trachelogenin ((-)-Trachelogenin) is an HCV entry inhibitor without genotype specificity, and with low cytotoxicity. Trachelogenin inhibits HCVcc infection and HCVpp cell entry in a dose-dependent manner with an IC50 of 0.325 and 0.259 μg/mL in HCVcc and HCVpp models, respectively. Trachelogenin exhibits effective antiviral, anti-inflammatory and analgesic effects .
    Trachelogenin
  • HY-109047

    AL-335

    HCV DNA/RNA Synthesis Infection
    Adafosbuvir (AL-335), a precursor compound of a uridine-based nucleotide analog polymerase (NS5B) inhibitor, has potent antiviral activity against HCV and acts as a potent inhibitor of HCV RNA polymerase .
    Adafosbuvir
  • HY-13998A

    ABT-333 sodium

    HCV DNA/RNA Synthesis Infection
    Dasabuvir (ABT-333) sodium is a nonnucleoside hepatitis C virus (HCV) polymerase inhibitor. Dasabuvir sodium inhibits RNA-dependent RNA polymerase encoded by the HCV NS5B gene. Dasabuvir sodium inhibits genotype 1a (strain H77) and 1b (strain Con1) replicons, with EC50 values of 7.7 and 1.8 nM, respectively .
    Dasabuvir sodium
  • HY-P4037

    HCV Infection
    HCV Core Protein (107-114) is a least immunogenic residue of the major linear HCV core regions. HCV Core Protein (107-114) is identified as the binding site within the region 101-118, which contains two residues differing between genotypes Ⅰ/Ⅱ and Ⅲ/Ⅵ. HCV Core Protein (107-114) might be a potential site for dissemination of HCV serotypes .
    HCV Core Protein (107-114)
  • HY-12633

    HCV Inflammation/Immunology
    GS-6620 is potent and selective HCV inhibitor. GS-6620 inhibits HCV replication in genotype 1-6 subgenomic replicons and genotype 2a infectious virus, with EC50 values of 0.048-0.68 μM. GS-6620 can be used for the researches of infection and inflammation, such as Hepatitis C Virus (HCV) .
    GS-6620
  • HY-102030

    HCV Infection
    BMS-961955 is an orally active inhibitor of HCV NS5B polymerase. BMS-961955 exhibits potent inhibitory activity against HCV genotype 1 (GT-1a/1b) replicons with EC50s of 4.3 nM and 7.9 nM, respectively. BMS-961955 can be used for the study of HCV infection .
    BMS-961955
  • HY-19557

    Drug Derivative HCV Protease Infection
    IDX-320 is a Pipecolic acid (HY-Y0669) derivative. IDX-320 inhibits NS3/4a proteases across genotypes 1a, 1b, 2a, and 4a with an IC50 0.8-1.9 nM. IDX-320 can be used in the research of HCV infection .
    IDX-320
  • HY-W103964

    HCV Infection
    HCV-IN-47 (Compound (R)-1) shows anti-hepatitis C virus (HCV) activity with an EC50 value of 0.032 μM. HCV-IN-47 is promising for research of hepatitis C virus pathogenesis, and host-virus interaction .
    HCV-IN-47
  • HY-131905S

    Isotope-Labeled Compounds HCV Protease HCV Infection Inflammation/Immunology Cancer
    BMS-986144 is a third-generation, pan-genotype (GT) NS3/4A protease inhibitor. BMS-986144 inhibits HCV replicon with EC50s of 2.3, 0.7, 1.0, 12, 8.0, and 5.8 nM for GT-1a, GT-1b, GT-2a, GT-3a, 1a R155X, and 1b D168V, respectively. BMS-986144 has the potential for the research of HCV infection .
    BMS-986144
  • HY-P4032

    HCV Inflammation/Immunology
    HCV Peptide (35-44), a HCV core protein at positions 35 to 44, is a HLA-A2-restricted CTL epitope. HCV Peptide (35-44) inhibits NK cell activity via two distinct mechanisms, directly via KIR2DL2/3, and synergistically via the CD94:NKG2A receptor .
    HCV Peptide (35-44)
  • HY-150760

    GSK2485852

    HCV Inflammation/Immunology
    GSK5852 (GSK2485852) is an HCV NS5B polymerase inhibitor, with an IC50 value of 50 nM. GSK5852 displays antiviral activity and inhibits HCV with EC50s of 3.0 nM (genotype 1a, GT1a) and 1.7 nM (GT1b), respectively .
    GSK5852
  • HY-U00213

    R803

    HCV Infection
    Furaprofen (R803) is an effective HCV replication inhibitor. Furaprofen (R803) is substantially more potent against genotype 1a and 1b replicons (EC50, ~30 nM) than against the genotype 2a replicon (EC50, ~1,000 nM).
    Furaprofen
  • HY-123186

    RG-7348

    HCV Infection
    MB-11362 is an orally active, selective HCV NS5B polymerase inhibitor and 4′-azidouridine triphosphate prodrug. MB-11362 can be converted to 4′-azidouridine triphosphate after oral administration. MB-11362 can be used in the research of HCV infection .
    MB-11362
  • HY-112047

    GSK2878175

    HCV Infection
    GSK8175 is a non-nucleoside polymerase (NS5B) inhibitor of hepatitis C virus (HCV). GSK8175 is a sulfonamide- N-benzoxaborole analog with low in vivo clearance across preclinical species and broad-spectrum activity against HCV replicons .
    GSK8175
  • HY-136267

    HCV Infection
    HCV-IN-30 (compound 48) is a HCV NS5A replication complex inhibitor, with IC50s of 901 and 102 nM for genotypes 1a and 1b replicons, respectively .
    HCV-IN-30
  • HY-128924

    Cyclophilin HCV Infection
    NIM258 is a potent nonimmunosuppressive cyclophilin inhibitor (cyclophilin A Kd = 1.2 nM) with anti-HCV activity (EC50 = 40 nM). NIM258 can be used for HCV infection research .
    NIM258
  • HY-111087

    HCV Protease Infection Inflammation/Immunology
    AZD-7295 is a HCV NS5A protein inhibitor, with an EC50 of 7 nM for GT-1b replicon .
    AZD-7295
  • HY-133247

    Drug Metabolite Others
    Daclatasvir Impurity B is the impurity of Daclatasvir. Daclatasvir is a potent HCV NS5A protein inhibitor .
    Daclatasvir Impurity B
  • HY-111204

    HCV Infection
    MK3281 (Compound 33) is a non-nucleoside hepatitis C virus (HCV) NS5B polymerase inhibitor, with an EC50 of 28 nM for gt1a .
    MK3281
  • HY-13998R

    ABT-333 (Standard)

    Reference Standards HCV DNA/RNA Synthesis Infection
    Dasabuvir (Standard) is the analytical standard of Dasabuvir. This product is intended for research and analytical applications. Dasabuvir (ABT-333) is a nonnucleoside hepatitis C virus (HCV) polymerase inhibitor. Dasabuvir inhibits RNA-dependent RNA polymerase encoded by the HCV NS5B gene. Dasabuvir inhibits genotype 1a (strain H77) and 1b (strain Con1) replicons, with EC50 values of 7.7 and 1.8 nM, respectively .
    Dasabuvir (Standard)
  • HY-118932

    HCV Infection
    HCV-IN-45 (Compound EI-1) is an inhibitor for hepatitis C virus (HCV), that inhibits 1a and 1b HCV pseudoparticles with EC50 of 0.134 and 0.027 μM. HCV-IN-45 inhibits 1a/2a and 1b/2a cell culture-adapted HCV (HCVcc), with EC50 of 0.024 and 0.012μM. HCV-IN-45 inhibits the entry of the virus into hepatocyte, and blocks the cell-cell spread .
    HCV-IN-45
  • HY-19941

    HCV Protease Infection
    Furaprevir is a potent and selective HCV NS3/4A protease inhibitor. Furaprevir can be used for genotype 1 hepatitis C research .
    Furaprevir
  • HY-169112

    HCV Infection
    HCV-IN-46 (compound 6d) is a HCV inhibitor with an EC50 value of 3.717 μM. HCV-IN-46 has antiviral activity .
    HCV-IN-46
  • HY-19481

    HCV Infection
    HCV-371 is a highly selective, potent, and low cytotoxicity HCV NSSB (EC50 = 4.8-6.1 μM) polymerase allosteric inhibitor. HCV-371 can be used for research on hepatitis C virus infection .
    HCV-371
  • HY-147885

    HCV Infection
    HCV-IN-41 (compound 4) is a highly potent hepatitis C virus (HCV) inhibitor with an EC50 value of 0.006762 nM, 5.183 nM, 1.365 nM and 142.2 nM for HCV genotype 1b, 2a, 3a and 4a, respectively. HCV-IN-41 reduces HCV RNA replication .
    HCV-IN-41

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: